Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 first-in-human study of anti-GD2 ADC M3554 in advanced solid tumors
jRCT2031240430Phase 1Recruiting
- Sponsor
- Merck KGaA
- Start
- Nov 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 1, open-label trial of M3554 in soft tissue sarcoma (STS), glioblastoma (GBM) and advanced nonhematological malignancy (2 arms), sponsored by Merck KGaA. Primary endpoints: Number of participants with dose-limiting toxicities and Number of participants with adverse events. Started Nov 2024; status: recruiting.
02
Drugs
M3554
03
Conditions
soft tissue sarcoma (STS)glioblastoma (GBM)advanced nonhematological malignancy
Beyond the preview
Go deeper on jRCT2031240430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240430.